HOME >> MEDICINE >> NEWS
Generics slow rising cost of prescription drugs in 2003

cost savings without shifting costs to members. Plan sponsors that implement GenericsWork can increase generic fill rate up to 70% and keep drug spending increases to less than 5% for the succeeding three years backed up by guarantees from Express Scripts.

"With our industry leading generic utilization rate, Express Scripts is proving that generic drugs are the key to managing the growing cost of prescription drugs and thus making it possible for plan sponsors to continue providing an attractive prescription benefit," said Barrett Toan, chairman and chief executive officer of Express Scripts. He added that GenericsWork uses methods proven by the evidence to increase the use of generics in prescription benefit plans of all sizes.

Overall, the Express Scripts Drug Trend Report found that plan sponsors that implemented two or more trend management program tools for the first time in 2003 saw their drug costs decline by 4.6%. Those who implemented one or more tools for the first time in 2003 saw their costs increase by only 5.9%. Plan sponsors who used at least one trend management program in 2003 saw their drug costs grow by 10.4%.

According to the Drug Trend Report, antihyperlipidemics replaced gastrointestinals as the leading therapy class of 2003 in overall spending. Growing 23.8% from 2002, the annual per-member spend for the class represented almost 14% of the total growth in prescription drug spend.

On the other hand, the annual per-member spend for estrogens and antihistamines decreased by 23.2% and 20.9% respectively because of the introduction of over-the-counter non-sedating antihistamine products and studies questioning the safety of hormone replacement therapy.

The top five categories in total drug spend, which include antihyperlipidemics; gastrointestinals; antidepressants; antihypertensives and anti-rheumatics, contributed nearly 45% of the grow
'"/>

Contact: Derrell Carter
derrell.carter@express-scripts.com
314-702-7584
Express Scripts, Inc.
8-Jun-2004


Page: 1 2 3

Related medicine news :

1. Celecoxib shows surprising activity against estrogen receptors
2. Breast cancer in Asian Americans is rising faster than in any other ethnic group
3. New survey reveals surprising insights into parental attitudes toward teenage sexual behavior
4. Breast cancers show surprising characteristics on MRI
5. Funding and distribution of inappropriate drugs add to rising global childhood malaria deaths
6. New prevalence study suggests dramatically rising numbers of people with Alzheimers disease
7. The rising cost of living with HIV
8. Surprising results for Ugandan HIV intervention trial
9. Concern over rising rates of syphilis in England
10. Breast cancer rising among Asian-American women
11. Surprising findings on Medicaid kids and the ER

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Generics slow rising cost prescription drugs

(Date:5/18/2013)... In a May 14, 2013 article entitled “Angelina Jolie ... Gene,” Fox News reported the movie star had opted ... a gene that doctors estimated gave her an 87 ... risk of ovarian cancer (go to: goo.gl/5JHBP). Ms. Jolie’s ... a blog post entitled “A Patient’s Journey: Angelina Jolie” ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Today, ... insurance agents’ role in Marketplaces . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and Human Services (HHS) recently released a much-anticipated ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- It ... but new research shows that college women are more likely ... than are college men. Much of this difference ... on a weekly basis is much lower for women than ... for men. But, there,s good reason for that difference. Women ...
(Date:5/18/2013)... 2013 TheBeautyPlace.com answers important questions about ... is not a result of stress, nutrient deficiency or ... Magazine, 70% of men suffer from male patterned baldness. ... renowned for hair transplant surgery, but additionally carries a ... known as Bosley Professional Strength. Their product line is ...
(Date:5/18/2013)... May 18, 2013 During Better Hearing ... should consider the legal protections they have, including the ... arise with their child’s treatment or hearing aid device, ... 1927, the American Speech-Language-Hearing Association has used the month ... to promote treatment, such as cochlear implants, which can ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
Cached News: